0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Custom Adeno-Associated Virus (AAV) Services Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-6F17784
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Custom Adeno Associated Virus AAV Services Market Research Report 2024
BUY CHAPTERS

Global Custom Adeno-Associated Virus (AAV) Services Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-6F17784
Report
October 2025
Pages:177
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Custom Adeno-Associated Virus (AAV) Services Market

The global Custom Adeno-Associated Virus (AAV) Services market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Custom Adeno-Associated Virus (AAV) services refer to specialized biotechnological offerings that involve the design, production, and optimization of AAV vectors tailored to specific research or therapeutic needs. These services are typically provided by biotech companies or research institutions and are widely used in gene therapy, genetic research, and preclinical studies.
Custom AAV services are crucial for advancing gene therapy research and developing novel therapeutic approaches for genetic disorders. They provide researchers and clinicians with the tools needed to precisely manipulate gene expression in various cell types and tissues, facilitating the development of effective and targeted treatments.
From a downstream perspective, Vaccine Development accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Custom Adeno-Associated Virus (AAV) Services leading manufacturers including Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics(MolMed), Gene Universal, Polyplus (Sartorius), etc., dominate supply; the top five capture approximately % of global revenue, with Thermo Fisher Scientific leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Custom Adeno-Associated Virus (AAV) Services market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Custom Adeno-Associated Virus (AAV) Services Market Report

Report Metric Details
Report Name Custom Adeno-Associated Virus (AAV) Services Market
Segment by Type
  • Adherent Culture
  • Suspension Culture
Segment by Application
  • Vaccine Development
  • Gene Therapy
  • Academic Scientific Research Institution
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics(MolMed), Gene Universal, Polyplus (Sartorius), CCRM, FUJIFILM Diosynth Biotechnologies, Biovian, Miltenyi Bioindustry, Aldevron, Takara Bio, Yposkesi, Genezen, Exthera, GenScript ProBio, EurekaBio, Obio Technology, GeneSail Biotech, VectorBuilder, WuXi ATU, Ubrigene, Porton Biologics, Pharmaron, PackGene Biotechnology
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Custom Adeno-Associated Virus (AAV) Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Custom Adeno-Associated Virus (AAV) Services Market report?

Ans: The main players in the Custom Adeno-Associated Virus (AAV) Services Market are Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics(MolMed), Gene Universal, Polyplus (Sartorius), CCRM, FUJIFILM Diosynth Biotechnologies, Biovian, Miltenyi Bioindustry, Aldevron, Takara Bio, Yposkesi, Genezen, Exthera, GenScript ProBio, EurekaBio, Obio Technology, GeneSail Biotech, VectorBuilder, WuXi ATU, Ubrigene, Porton Biologics, Pharmaron, PackGene Biotechnology

What are the Application segmentation covered in the Custom Adeno-Associated Virus (AAV) Services Market report?

Ans: The Applications covered in the Custom Adeno-Associated Virus (AAV) Services Market report are Vaccine Development, Gene Therapy, Academic Scientific Research Institution, Others

What are the Type segmentation covered in the Custom Adeno-Associated Virus (AAV) Services Market report?

Ans: The Types covered in the Custom Adeno-Associated Virus (AAV) Services Market report are Adherent Culture, Suspension Culture

1 Study Coverage
1.1 Introduction to Custom Adeno-Associated Virus (AAV) Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Custom Adeno-Associated Virus (AAV) Services Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Adherent Culture
1.2.3 Suspension Culture
1.3 Market Segmentation by Application
1.3.1 Global Custom Adeno-Associated Virus (AAV) Services Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Vaccine Development
1.3.3 Gene Therapy
1.3.4 Academic Scientific Research Institution
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Custom Adeno-Associated Virus (AAV) Services Revenue Estimates and Forecasts 2020-2031
2.2 Global Custom Adeno-Associated Virus (AAV) Services Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Custom Adeno-Associated Virus (AAV) Services Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Custom Adeno-Associated Virus (AAV) Services Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Adherent Culture Market Size by Players
3.3.2 Suspension Culture Market Size by Players
3.4 Global Custom Adeno-Associated Virus (AAV) Services Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Custom Adeno-Associated Virus (AAV) Services Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Custom Adeno-Associated Virus (AAV) Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Custom Adeno-Associated Virus (AAV) Services Market Size by Type (2020-2031)
6.4 North America Custom Adeno-Associated Virus (AAV) Services Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Custom Adeno-Associated Virus (AAV) Services Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Custom Adeno-Associated Virus (AAV) Services Market Size by Type (2020-2031)
7.4 Europe Custom Adeno-Associated Virus (AAV) Services Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Custom Adeno-Associated Virus (AAV) Services Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Custom Adeno-Associated Virus (AAV) Services Market Size by Type (2020-2031)
8.4 Asia-Pacific Custom Adeno-Associated Virus (AAV) Services Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Custom Adeno-Associated Virus (AAV) Services Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Custom Adeno-Associated Virus (AAV) Services Market Size by Type (2020-2031)
9.4 Central and South America Custom Adeno-Associated Virus (AAV) Services Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Custom Adeno-Associated Virus (AAV) Services Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Custom Adeno-Associated Virus (AAV) Services Market Size by Type (2020-2031)
10.4 Middle East and Africa Custom Adeno-Associated Virus (AAV) Services Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Custom Adeno-Associated Virus (AAV) Services Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Corporation Information
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.1.4 Thermo Fisher Scientific Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.1.5 Thermo Fisher Scientific Custom Adeno-Associated Virus (AAV) Services Revenue by Product in 2024
11.1.6 Thermo Fisher Scientific Custom Adeno-Associated Virus (AAV) Services Revenue by Application in 2024
11.1.7 Thermo Fisher Scientific Custom Adeno-Associated Virus (AAV) Services Revenue by Geographic Area in 2024
11.1.8 Thermo Fisher Scientific Custom Adeno-Associated Virus (AAV) Services SWOT Analysis
11.1.9 Thermo Fisher Scientific Recent Developments
11.2 Lonza
11.2.1 Lonza Corporation Information
11.2.2 Lonza Business Overview
11.2.3 Lonza Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.2.4 Lonza Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.2.5 Lonza Custom Adeno-Associated Virus (AAV) Services Revenue by Product in 2024
11.2.6 Lonza Custom Adeno-Associated Virus (AAV) Services Revenue by Application in 2024
11.2.7 Lonza Custom Adeno-Associated Virus (AAV) Services Revenue by Geographic Area in 2024
11.2.8 Lonza Custom Adeno-Associated Virus (AAV) Services SWOT Analysis
11.2.9 Lonza Recent Developments
11.3 Catalent
11.3.1 Catalent Corporation Information
11.3.2 Catalent Business Overview
11.3.3 Catalent Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.3.4 Catalent Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.3.5 Catalent Custom Adeno-Associated Virus (AAV) Services Revenue by Product in 2024
11.3.6 Catalent Custom Adeno-Associated Virus (AAV) Services Revenue by Application in 2024
11.3.7 Catalent Custom Adeno-Associated Virus (AAV) Services Revenue by Geographic Area in 2024
11.3.8 Catalent Custom Adeno-Associated Virus (AAV) Services SWOT Analysis
11.3.9 Catalent Recent Developments
11.4 Charles River
11.4.1 Charles River Corporation Information
11.4.2 Charles River Business Overview
11.4.3 Charles River Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.4.4 Charles River Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.4.5 Charles River Custom Adeno-Associated Virus (AAV) Services Revenue by Product in 2024
11.4.6 Charles River Custom Adeno-Associated Virus (AAV) Services Revenue by Application in 2024
11.4.7 Charles River Custom Adeno-Associated Virus (AAV) Services Revenue by Geographic Area in 2024
11.4.8 Charles River Custom Adeno-Associated Virus (AAV) Services SWOT Analysis
11.4.9 Charles River Recent Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Business Overview
11.5.3 Merck Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.5.4 Merck Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.5.5 Merck Custom Adeno-Associated Virus (AAV) Services Revenue by Product in 2024
11.5.6 Merck Custom Adeno-Associated Virus (AAV) Services Revenue by Application in 2024
11.5.7 Merck Custom Adeno-Associated Virus (AAV) Services Revenue by Geographic Area in 2024
11.5.8 Merck Custom Adeno-Associated Virus (AAV) Services SWOT Analysis
11.5.9 Merck Recent Developments
11.6 SK pharmteco
11.6.1 SK pharmteco Corporation Information
11.6.2 SK pharmteco Business Overview
11.6.3 SK pharmteco Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.6.4 SK pharmteco Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.6.5 SK pharmteco Recent Developments
11.7 Oxford Biomedica
11.7.1 Oxford Biomedica Corporation Information
11.7.2 Oxford Biomedica Business Overview
11.7.3 Oxford Biomedica Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.7.4 Oxford Biomedica Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.7.5 Oxford Biomedica Recent Developments
11.8 AGC Biologics(MolMed)
11.8.1 AGC Biologics(MolMed) Corporation Information
11.8.2 AGC Biologics(MolMed) Business Overview
11.8.3 AGC Biologics(MolMed) Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.8.4 AGC Biologics(MolMed) Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.8.5 AGC Biologics(MolMed) Recent Developments
11.9 Gene Universal
11.9.1 Gene Universal Corporation Information
11.9.2 Gene Universal Business Overview
11.9.3 Gene Universal Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.9.4 Gene Universal Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.9.5 Gene Universal Recent Developments
11.10 Polyplus (Sartorius)
11.10.1 Polyplus (Sartorius) Corporation Information
11.10.2 Polyplus (Sartorius) Business Overview
11.10.3 Polyplus (Sartorius) Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.10.4 Polyplus (Sartorius) Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 CCRM
11.11.1 CCRM Corporation Information
11.11.2 CCRM Business Overview
11.11.3 CCRM Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.11.4 CCRM Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.11.5 CCRM Recent Developments
11.12 FUJIFILM Diosynth Biotechnologies
11.12.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.12.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.12.3 FUJIFILM Diosynth Biotechnologies Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.12.4 FUJIFILM Diosynth Biotechnologies Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.12.5 FUJIFILM Diosynth Biotechnologies Recent Developments
11.13 Biovian
11.13.1 Biovian Corporation Information
11.13.2 Biovian Business Overview
11.13.3 Biovian Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.13.4 Biovian Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.13.5 Biovian Recent Developments
11.14 Miltenyi Bioindustry
11.14.1 Miltenyi Bioindustry Corporation Information
11.14.2 Miltenyi Bioindustry Business Overview
11.14.3 Miltenyi Bioindustry Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.14.4 Miltenyi Bioindustry Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.14.5 Miltenyi Bioindustry Recent Developments
11.15 Aldevron
11.15.1 Aldevron Corporation Information
11.15.2 Aldevron Business Overview
11.15.3 Aldevron Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.15.4 Aldevron Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.15.5 Aldevron Recent Developments
11.16 Takara Bio
11.16.1 Takara Bio Corporation Information
11.16.2 Takara Bio Business Overview
11.16.3 Takara Bio Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.16.4 Takara Bio Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.16.5 Takara Bio Recent Developments
11.17 Yposkesi
11.17.1 Yposkesi Corporation Information
11.17.2 Yposkesi Business Overview
11.17.3 Yposkesi Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.17.4 Yposkesi Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.17.5 Yposkesi Recent Developments
11.18 Genezen
11.18.1 Genezen Corporation Information
11.18.2 Genezen Business Overview
11.18.3 Genezen Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.18.4 Genezen Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.18.5 Genezen Recent Developments
11.19 Exthera
11.19.1 Exthera Corporation Information
11.19.2 Exthera Business Overview
11.19.3 Exthera Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.19.4 Exthera Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.19.5 Exthera Recent Developments
11.20 GenScript ProBio
11.20.1 GenScript ProBio Corporation Information
11.20.2 GenScript ProBio Business Overview
11.20.3 GenScript ProBio Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.20.4 GenScript ProBio Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.20.5 GenScript ProBio Recent Developments
11.21 EurekaBio
11.21.1 EurekaBio Corporation Information
11.21.2 EurekaBio Business Overview
11.21.3 EurekaBio Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.21.4 EurekaBio Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.21.5 EurekaBio Recent Developments
11.22 Obio Technology
11.22.1 Obio Technology Corporation Information
11.22.2 Obio Technology Business Overview
11.22.3 Obio Technology Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.22.4 Obio Technology Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.22.5 Obio Technology Recent Developments
11.23 GeneSail Biotech
11.23.1 GeneSail Biotech Corporation Information
11.23.2 GeneSail Biotech Business Overview
11.23.3 GeneSail Biotech Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.23.4 GeneSail Biotech Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.23.5 GeneSail Biotech Recent Developments
11.24 VectorBuilder
11.24.1 VectorBuilder Corporation Information
11.24.2 VectorBuilder Business Overview
11.24.3 VectorBuilder Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.24.4 VectorBuilder Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.24.5 VectorBuilder Recent Developments
11.25 WuXi ATU
11.25.1 WuXi ATU Corporation Information
11.25.2 WuXi ATU Business Overview
11.25.3 WuXi ATU Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.25.4 WuXi ATU Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.25.5 WuXi ATU Recent Developments
11.26 Ubrigene
11.26.1 Ubrigene Corporation Information
11.26.2 Ubrigene Business Overview
11.26.3 Ubrigene Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.26.4 Ubrigene Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.26.5 Ubrigene Recent Developments
11.27 Porton Biologics
11.27.1 Porton Biologics Corporation Information
11.27.2 Porton Biologics Business Overview
11.27.3 Porton Biologics Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.27.4 Porton Biologics Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.27.5 Porton Biologics Recent Developments
11.28 Pharmaron
11.28.1 Pharmaron Corporation Information
11.28.2 Pharmaron Business Overview
11.28.3 Pharmaron Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.28.4 Pharmaron Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.28.5 Pharmaron Recent Developments
11.29 PackGene Biotechnology
11.29.1 PackGene Biotechnology Corporation Information
11.29.2 PackGene Biotechnology Business Overview
11.29.3 PackGene Biotechnology Custom Adeno-Associated Virus (AAV) Services Product Features and Attributes
11.29.4 PackGene Biotechnology Custom Adeno-Associated Virus (AAV) Services Revenue and Gross Margin (2020-2025)
11.29.5 PackGene Biotechnology Recent Developments
12 Custom Adeno-Associated Virus (AAV) ServicesIndustry Chain Analysis
12.1 Custom Adeno-Associated Virus (AAV) Services Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Custom Adeno-Associated Virus (AAV) Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Custom Adeno-Associated Virus (AAV) Services Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
 Table 1. Global Custom Adeno-Associated Virus (AAV) Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Custom Adeno-Associated Virus (AAV) Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Custom Adeno-Associated Virus (AAV) Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Custom Adeno-Associated Virus (AAV) Services Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Custom Adeno-Associated Virus (AAV) Services Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Custom Adeno-Associated Virus (AAV) Services Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Custom Adeno-Associated Virus (AAV) Services Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Custom Adeno-Associated Virus (AAV) Services by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Custom Adeno-Associated Virus (AAV) Services as of 2024)
 Table 11. Global Custom Adeno-Associated Virus (AAV) Services Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Custom Adeno-Associated Virus (AAV) Services Companies Headquarters
 Table 13. Global Custom Adeno-Associated Virus (AAV) Services Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Custom Adeno-Associated Virus (AAV) Services Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Custom Adeno-Associated Virus (AAV) Services Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Custom Adeno-Associated Virus (AAV) Services Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Custom Adeno-Associated Virus (AAV) Services Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Custom Adeno-Associated Virus (AAV) Services High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Custom Adeno-Associated Virus (AAV) Services Growth Accelerators and Market Barriers
 Table 25. North America Custom Adeno-Associated Virus (AAV) Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Custom Adeno-Associated Virus (AAV) Services Growth Accelerators and Market Barriers
 Table 27. Europe Custom Adeno-Associated Virus (AAV) Services Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Custom Adeno-Associated Virus (AAV) Services Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Custom Adeno-Associated Virus (AAV) Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Custom Adeno-Associated Virus (AAV) Services Investment Opportunities and Key Challenges
 Table 31. Central and South America Custom Adeno-Associated Virus (AAV) Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Custom Adeno-Associated Virus (AAV) Services Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Custom Adeno-Associated Virus (AAV) Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Thermo Fisher Scientific Corporation Information
 Table 35. Thermo Fisher Scientific Description and Major Businesses
 Table 36. Thermo Fisher Scientific Product Features and Attributes
 Table 37. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Thermo Fisher Scientific Revenue Proportion by Product in 2024
 Table 39. Thermo Fisher Scientific Revenue Proportion by Application in 2024
 Table 40. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
 Table 41. Thermo Fisher Scientific Custom Adeno-Associated Virus (AAV) Services SWOT Analysis
 Table 42. Thermo Fisher Scientific Recent Developments
 Table 43. Lonza Corporation Information
 Table 44. Lonza Description and Major Businesses
 Table 45. Lonza Product Features and Attributes
 Table 46. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Lonza Revenue Proportion by Product in 2024
 Table 48. Lonza Revenue Proportion by Application in 2024
 Table 49. Lonza Revenue Proportion by Geographic Area in 2024
 Table 50. Lonza Custom Adeno-Associated Virus (AAV) Services SWOT Analysis
 Table 51. Lonza Recent Developments
 Table 52. Catalent Corporation Information
 Table 53. Catalent Description and Major Businesses
 Table 54. Catalent Product Features and Attributes
 Table 55. Catalent Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Catalent Revenue Proportion by Product in 2024
 Table 57. Catalent Revenue Proportion by Application in 2024
 Table 58. Catalent Revenue Proportion by Geographic Area in 2024
 Table 59. Catalent Custom Adeno-Associated Virus (AAV) Services SWOT Analysis
 Table 60. Catalent Recent Developments
 Table 61. Charles River Corporation Information
 Table 62. Charles River Description and Major Businesses
 Table 63. Charles River Product Features and Attributes
 Table 64. Charles River Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Charles River Revenue Proportion by Product in 2024
 Table 66. Charles River Revenue Proportion by Application in 2024
 Table 67. Charles River Revenue Proportion by Geographic Area in 2024
 Table 68. Charles River Custom Adeno-Associated Virus (AAV) Services SWOT Analysis
 Table 69. Charles River Recent Developments
 Table 70. Merck Corporation Information
 Table 71. Merck Description and Major Businesses
 Table 72. Merck Product Features and Attributes
 Table 73. Merck Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Merck Revenue Proportion by Product in 2024
 Table 75. Merck Revenue Proportion by Application in 2024
 Table 76. Merck Revenue Proportion by Geographic Area in 2024
 Table 77. Merck Custom Adeno-Associated Virus (AAV) Services SWOT Analysis
 Table 78. Merck Recent Developments
 Table 79. SK pharmteco Corporation Information
 Table 80. SK pharmteco Description and Major Businesses
 Table 81. SK pharmteco Product Features and Attributes
 Table 82. SK pharmteco Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. SK pharmteco Recent Developments
 Table 84. Oxford Biomedica Corporation Information
 Table 85. Oxford Biomedica Description and Major Businesses
 Table 86. Oxford Biomedica Product Features and Attributes
 Table 87. Oxford Biomedica Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Oxford Biomedica Recent Developments
 Table 89. AGC Biologics(MolMed) Corporation Information
 Table 90. AGC Biologics(MolMed) Description and Major Businesses
 Table 91. AGC Biologics(MolMed) Product Features and Attributes
 Table 92. AGC Biologics(MolMed) Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. AGC Biologics(MolMed) Recent Developments
 Table 94. Gene Universal Corporation Information
 Table 95. Gene Universal Description and Major Businesses
 Table 96. Gene Universal Product Features and Attributes
 Table 97. Gene Universal Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Gene Universal Recent Developments
 Table 99. Polyplus (Sartorius) Corporation Information
 Table 100. Polyplus (Sartorius) Description and Major Businesses
 Table 101. Polyplus (Sartorius) Product Features and Attributes
 Table 102. Polyplus (Sartorius) Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Polyplus (Sartorius) Recent Developments
 Table 104. CCRM Corporation Information
 Table 105. CCRM Description and Major Businesses
 Table 106. CCRM Product Features and Attributes
 Table 107. CCRM Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. CCRM Recent Developments
 Table 109. FUJIFILM Diosynth Biotechnologies Corporation Information
 Table 110. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
 Table 111. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
 Table 112. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. FUJIFILM Diosynth Biotechnologies Recent Developments
 Table 114. Biovian Corporation Information
 Table 115. Biovian Description and Major Businesses
 Table 116. Biovian Product Features and Attributes
 Table 117. Biovian Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Biovian Recent Developments
 Table 119. Miltenyi Bioindustry Corporation Information
 Table 120. Miltenyi Bioindustry Description and Major Businesses
 Table 121. Miltenyi Bioindustry Product Features and Attributes
 Table 122. Miltenyi Bioindustry Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 123. Miltenyi Bioindustry Recent Developments
 Table 124. Aldevron Corporation Information
 Table 125. Aldevron Description and Major Businesses
 Table 126. Aldevron Product Features and Attributes
 Table 127. Aldevron Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 128. Aldevron Recent Developments
 Table 129. Takara Bio Corporation Information
 Table 130. Takara Bio Description and Major Businesses
 Table 131. Takara Bio Product Features and Attributes
 Table 132. Takara Bio Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 133. Takara Bio Recent Developments
 Table 134. Yposkesi Corporation Information
 Table 135. Yposkesi Description and Major Businesses
 Table 136. Yposkesi Product Features and Attributes
 Table 137. Yposkesi Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 138. Yposkesi Recent Developments
 Table 139. Genezen Corporation Information
 Table 140. Genezen Description and Major Businesses
 Table 141. Genezen Product Features and Attributes
 Table 142. Genezen Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 143. Genezen Recent Developments
 Table 144. Exthera Corporation Information
 Table 145. Exthera Description and Major Businesses
 Table 146. Exthera Product Features and Attributes
 Table 147. Exthera Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 148. Exthera Recent Developments
 Table 149. GenScript ProBio Corporation Information
 Table 150. GenScript ProBio Description and Major Businesses
 Table 151. GenScript ProBio Product Features and Attributes
 Table 152. GenScript ProBio Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 153. GenScript ProBio Recent Developments
 Table 154. EurekaBio Corporation Information
 Table 155. EurekaBio Description and Major Businesses
 Table 156. EurekaBio Product Features and Attributes
 Table 157. EurekaBio Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 158. EurekaBio Recent Developments
 Table 159. Obio Technology Corporation Information
 Table 160. Obio Technology Description and Major Businesses
 Table 161. Obio Technology Product Features and Attributes
 Table 162. Obio Technology Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 163. Obio Technology Recent Developments
 Table 164. GeneSail Biotech Corporation Information
 Table 165. GeneSail Biotech Description and Major Businesses
 Table 166. GeneSail Biotech Product Features and Attributes
 Table 167. GeneSail Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 168. GeneSail Biotech Recent Developments
 Table 169. VectorBuilder Corporation Information
 Table 170. VectorBuilder Description and Major Businesses
 Table 171. VectorBuilder Product Features and Attributes
 Table 172. VectorBuilder Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 173. VectorBuilder Recent Developments
 Table 174. WuXi ATU Corporation Information
 Table 175. WuXi ATU Description and Major Businesses
 Table 176. WuXi ATU Product Features and Attributes
 Table 177. WuXi ATU Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 178. WuXi ATU Recent Developments
 Table 179. Ubrigene Corporation Information
 Table 180. Ubrigene Description and Major Businesses
 Table 181. Ubrigene Product Features and Attributes
 Table 182. Ubrigene Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 183. Ubrigene Recent Developments
 Table 184. Porton Biologics Corporation Information
 Table 185. Porton Biologics Description and Major Businesses
 Table 186. Porton Biologics Product Features and Attributes
 Table 187. Porton Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 188. Porton Biologics Recent Developments
 Table 189. Pharmaron Corporation Information
 Table 190. Pharmaron Description and Major Businesses
 Table 191. Pharmaron Product Features and Attributes
 Table 192. Pharmaron Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 193. Pharmaron Recent Developments
 Table 194. PackGene Biotechnology Corporation Information
 Table 195. PackGene Biotechnology Description and Major Businesses
 Table 196. PackGene Biotechnology Product Features and Attributes
 Table 197. PackGene Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 198. PackGene Biotechnology Recent Developments
 Table 199. Raw Materials Key Suppliers
 Table 200. Distributors List
 Table 201. Market Trends and Market Evolution
 Table 202. Market Drivers and Opportunities
 Table 203. Market Challenges, Risks, and Restraints
 Table 204. Research Programs/Design for This Report
 Table 205. Key Data Information from Secondary Sources
 Table 206. Key Data Information from Primary Sources


List of Figures
 Figure 1. Custom Adeno-Associated Virus (AAV) Services Product Picture
 Figure 2. Global Custom Adeno-Associated Virus (AAV) Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Adherent Culture Product Picture
 Figure 4. Suspension Culture Product Picture
 Figure 5. Global Custom Adeno-Associated Virus (AAV) Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Vaccine Development
 Figure 7. Gene Therapy
 Figure 8. Academic Scientific Research Institution
 Figure 9. Others
 Figure 10. Custom Adeno-Associated Virus (AAV) Services Report Years Considered
 Figure 11. Global Custom Adeno-Associated Virus (AAV) Services Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Custom Adeno-Associated Virus (AAV) Services Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Custom Adeno-Associated Virus (AAV) Services Revenue Market Share by Region (2020-2031)
 Figure 15. Global Custom Adeno-Associated Virus (AAV) Services Revenue Market Share Ranking (2024)
 Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 17. Adherent Culture Revenue Market Share by Player in 2024
 Figure 18. Suspension Culture Revenue Market Share by Player in 2024
 Figure 19. Global Custom Adeno-Associated Virus (AAV) Services Revenue Market Share by Type (2020-2031)
 Figure 20. Global Custom Adeno-Associated Virus (AAV) Services Revenue Market Share by Application (2020-2031)
 Figure 21. North America Custom Adeno-Associated Virus (AAV) Services Revenue YoY (2020-2031) & (US$ Million)
 Figure 22. North America Top 5 Players Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) in 2024
 Figure 23. North America Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) by Type (2020 - 2031)
 Figure 24. North America Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) by Application (2020-2031)
 Figure 25. US Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 26. Canada Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 27. Mexico Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 28. Europe Custom Adeno-Associated Virus (AAV) Services Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. Europe Top 5 Players Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) in 2024
 Figure 30. Europe Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) by Type (2020-2031)
 Figure 31. Europe Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) by Application (2020-2031)
 Figure 32. Germany Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 33. France Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 34. U.K. Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 35. Italy Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 36. Russia Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific Custom Adeno-Associated Virus (AAV) Services Revenue YoY (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Top 8 Players Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) in 2024
 Figure 39. Asia-Pacific Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Asia-Pacific Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) by Application (2020-2031)
 Figure 41. Indonesia Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 42. Japan Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 43. South Korea Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 44. Australia Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 45. India Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 46. Indonesia Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 47. Vietnam Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 48. Malaysia Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 49. Philippines Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 50. Singapore Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2031) & (US$ Million)
 Figure 51. Central and South America Custom Adeno-Associated Virus (AAV) Services Revenue YoY (2020-2031) & (US$ Million)
 Figure 52. Central and South America Top 5 Players Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) in 2024
 Figure 53. Central and South America Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) by Type (2020-2031)
 Figure 54. Central and South America Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) by Application (2020-2031)
 Figure 55. Brazil Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2025) & (US$ Million)
 Figure 56. Argentina Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2025) & (US$ Million)
 Figure 57. Middle East and Africa Custom Adeno-Associated Virus (AAV) Services Revenue YoY (2020-2031) & (US$ Million)
 Figure 58. Middle East and Africa Top 5 Players Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) in 2024
 Figure 59. South America Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) by Type (2020-2031)
 Figure 60. Middle East and Africa Custom Adeno-Associated Virus (AAV) Services Revenue (US$ Million) by Application (2020-2031)
 Figure 61. GCC Countries Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2025) & (US$ Million)
 Figure 62. Israel Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2025) & (US$ Million)
 Figure 63. Egypt Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2025) & (US$ Million)
 Figure 64. South Africa Custom Adeno-Associated Virus (AAV) Services Revenue (2020-2025) & (US$ Million)
 Figure 65. Custom Adeno-Associated Virus (AAV) Services Industry Chain Mapping
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS